In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
Findings seen among subgroup of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Project Renewal is an Oncology Center of Excellence initiative that aims to update the labeling information for certain older oncology drugs.
Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.
Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.
Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Ribociclib plus endocrine therapy prolongs progression-free survival when compared with chemotherapy in HR+/ HER2− advanced breast cancer.
A retrospective study revealed characteristics of patients with metastatic breast cancer who are not likely to receive first-line systemic therapy.